INSMED Inc Q3 FY2024 earnings call

Management Statement and Operational Highlights:

• Brensocatib Progress: Presented subpopulation data from ASPEN trial, expects to file NDA in Q4 2024; U.S. sales force expanded to 184 reps, trained and deployed. Phase 2 studies in CRS without nasal polyps and hidradenitis suppurativa progressing.
• ARIKAYCE Performance: Seventh consecutive quarter of double-digit y-o-y revenue growth; ENCORE study enrollment exceeded target, on track for Q1 2026 readout.
• TPIP Updates: Enrollment in PAH Phase 2 study exceeded 90% of target; work ongoing to optimize TPIP manufacturing for commercial readiness; expect to kick off Phase 3 program for PH-ILD in H2 2025.
• Financial Actions: Called $225M convertible notes, raised ~$371M via ATM, restructured $350M term loan with Pharmakon, improving balance sheet and cash position.

Segment Performance:

• ARIKAYCE: Posted seventh consecutive quarter of double-digit year-over-year revenue growth. Global net revenues for the quarter were $93.4 million, with U.S. net revenue at $66.9 million (up 13% y-o-y), Japan at $21 million (up 31% y-o-y), and Europe/Rest of World at $5.6 million (up 45% y-o-y). ARIKAYCE contributes significantly to overall revenue.
• Brensocatib: Preparations for U.S. launch ongoing, with sales force expanded to 184 reps. Phase 2 studies in CRS without nasal polyps and hidradenitis suppurativa progressing.
• TPIP: Enrollment in Phase 2 study for PAH exceeded 90% of target, on track for top-line results in H2 2025; work ongoing to optimize manufacturing for commercial readiness.

Guidance:

• Expect to file NDA for brensocatib in Q4 2024; if accepted, expect FDA decision timeline in Q1 2025.
• Full year 2024 global revenue guidance remains $340M to $360M, with Q3 performance keeping on track.
• Anticipate brensocatib launch in 2025 pending regulatory approval, with strong potential based on analogs in respiratory space.

Risks:

• Uncertainties related to regulatory approvals for brensocatib and other programs.
• Market adoption challenges for new products, including brensocatib and TPIP.
• Variability in clinical trial enrollments and outcomes, particularly in difficult-to-treat patient populations.

Question and Answer: Q: Talk more about expanded sales force for brensocatib launch and disease state awareness.

A: Will Lewis mentioned sales force is experienced, culturally fit, and similar to ARIKAYCE launch strategy with disease state awareness.

Q: Thoughts on labeling language for brensocatib.

A: Martina Flammer expects broad label language for bronchiectasis, including adolescent patients.

Q: Japan revenue performance and FDA accelerated approval for ARIKAYCE.

A: Sara Bonstein noted Japan had 30%+ growth, Will Lewis discussed low probability but prudent dialogue for FDA accelerated approval of ARIKAYCE label expansion.